Patent · US Active

Antibodies specifically binding to the epidermal growth factor receptor

US8748175B2 · kind B2 · utility

2Cited by
0References
30Claims
0Family size

Assignee

Inventors

Key dates

Filing dateNov 2, 2009
Grant dateJun 10, 2014
Priority date—
Expiry dateDec 16, 2029

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2317/565
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Provided are antibodies specifically binding to the epidermal growth factor receptor (EGFR) which are effective for the treatment of EGFR-mediated cancers.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.